Otsuka reported top-line Phase IIIb results for centanafadine, its once-daily non-stimulant candidate for ADHD with comorbid anxiety. In the study, centanafadine met the primary endpoint defined by improvements on the Adult Investigator Symptom Rating Scale at week 8 compared with placebo. The update extends Otsuka’s strategy to broaden non-stimulant options for adult ADHD populations where anxiety comorbidity complicates treatment. It also reinforces the company’s pipeline momentum beyond single-dimension indications. Investors and clinicians will watch what Otsuka reports next on tolerability, effect size durability, and label-enabling details as the program advances.